Literature DB >> 21785086

Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.

Jin-Young Choi1, Myeong-Jin Kim, Young Nyun Park, Jeong Min Lee, Sun Kook Yoo, Sun Young Rha, Jae Yeon Seok.   

Abstract

OBJECTIVE: The purpose of this study was to assess whether gadoxetate disodium-enhanced hepatobiliary phase MRI could predict the histologic factors of hepatocellular carcinomas (HCCs).
MATERIALS AND METHODS: Fifty-three HCCs histopathologically proved by surgery in 51 patients were evaluated retrospectively. All patients underwent gadoxetate disodium-enhanced MRI before surgical resection. The differences in contrast enhancement ratio of the lesions and differences in contrast-to-noise ratio (CNR) among the histologic grades of HCC were compared by using the Kruskal-Wallis test. The Spearman method was used to determine the correlations among contrast enhancement ratio, CNR, cell density ratio, and positivity for anti-hepatocyte antibody, keratin 7, and keratin 19.
RESULTS: Of 53 HCCs, 50 showed low signal intensity on hepatobiliary phase images, whereas three HCCs were hyperintense on hepatobiliary phase images compared with surrounding hepatic parenchyma. Although well-differentiated HCCs tended to show higher contrast enhancement, there was no statistical significance between contrast enhancement ratio of the tumors and histologic grade (p = 0.414). No significant difference was observed between CNR and histologic grade (p = 0.965). The contrast enhancement ratios of the tumors were significantly lower in the keratin 19-positive group than in the keratin 19-negative group (p = 0.015). There was no significant correlation among contrast enhancement ratio, anti-hepatocyte antibody positivity, cell density ratio, and keratin 7 positivity (p > 0.05).
CONCLUSION: The contrast enhancement ratio and CNR of HCCs were not correlated with histologic grades. The contrast enhancement ratio was significantly lower in keratin 19-positive HCCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785086     DOI: 10.2214/AJR.10.5439

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  21 in total

Review 1.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

2.  Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yuichiro Kubo; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Hiroshi Honda
Journal:  Eur Radiol       Date:  2014-07-26       Impact factor: 5.315

3.  Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.

Authors:  Jieun Koh; Yong Eun Chung; Ji Hae Nahm; Ha Yan Kim; Kyung-Sik Kim; Young Nyun Park; Myeong-Jin Kim; Jin-Young Choi
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

4.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

Review 5.  [CT and MRI of the liver: when, what, why?]

Authors:  J Budjan; S O Schoenberg; U I Attenberger
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

6.  Prediction of histological grade of hepatocellular carcinoma using quantitative diffusion-weighted MRI: a retrospective multivendor study.

Authors:  Yusuke Ogihara; Yoshio Kitazume; Yoshihiro Iwasa; Shinichi Taura; Yoshiro Himeno; Tomo Kimura; Seishi Sawano; Shigehiko Terada; Minoru Tanabe; Yukihisa Saida; Ukihide Tateishi
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

Review 7.  Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression.

Authors:  Hyungjin Rhee; Haeryoung Kim; Young Nyun Park
Journal:  Liver Cancer       Date:  2020-10-23       Impact factor: 11.740

Review 8.  Hepatoblastoma imaging with gadoxetate disodium-enhanced MRI--typical, atypical, pre- and post-treatment evaluation.

Authors:  Arthur B Meyers; Alexander J Towbin; James I Geller; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2012-03-15

9.  Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma.

Authors:  Jae Hyun Han; Dong Goo Kim; Gun Hyung Na; Eun Young Kim; Soo Ho Lee; Tae Ho Hong; Young Kyoung You
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 10.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.